Across Tennessee's research institutions, scientists are developing technologies that could fundamentally change how diseases are diagnosed and treated, with innovations moving from university laboratories directly into clinical practice and patient care. From artificial intelligence tools that analyze heart signals to experimental drugs targeting resistant cancers, these breakthroughs represent a critical bridge between scientific discovery and real-world medical impact .

How Are Researchers Turning Lab Discoveries Into Treatments?

The journey from laboratory research to patient benefit involves several key steps that ensure innovations are both scientifically rigorous and practically applicable. University research foundations play a crucial role in this translation process, providing support and resources that help move discoveries beyond academic papers into the hands of clinicians and patients .

• Research Collaboration: Innovations often emerge from partnerships between university departments and external institutions, combining expertise across multiple disciplines to solve complex medical problems.
• Startup Development: Promising discoveries are spun out into dedicated companies that can focus on development, regulatory approval, and commercialization of new treatments and devices.
• Regulatory Pathways: Technologies receive designations like FDA Breakthrough Device status, which accelerates development for innovations that may provide more effective diagnosis or treatment of life-threatening diseases.
• Clinical Integration: Once approved or licensed, innovations are distributed through established medical channels, allowing hospitals and clinics to implement new tools in patient care.

Can Artificial Intelligence Detect Heart Disease Before Symptoms Appear?

One of the most promising applications emerging from university research involves using artificial intelligence to analyze electrocardiograms (ECGs), the standard heart rhythm tests that have been read the same way for nearly a century. A digital health startup called 9+1AI, spun out of research collaborations involving the University of Tennessee Health Science Center College of Medicine in Memphis and Wake Forest School of Medicine, is developing AI tools that detect cardiovascular disease earlier and more accurately than traditional methods .

The technology recently received FDA Breakthrough Device Designation, a status reserved for innovations that may provide superior diagnosis or treatment of life-threatening diseases. Heart failure remains one of the most common and costly medical conditions in the United States, affecting millions of adults and often going undiagnosed until symptoms become severe .

"We believe the ECG holds far more information than clinicians have traditionally been able to extract. Artificial intelligence allows us to detect patterns in the signal that may reveal disease long before symptoms appear," said Dr. Robert Davis, co-founder and chief medical officer of 9+1AI.

Dr. Robert Davis, Co-founder and Chief Medical Officer, 9+1AI

Because the system can analyze ECG data from hospitals, clinics, or wearable devices such as smartwatches, the technology could eventually support remote monitoring and telehealth, potentially enabling earlier treatment for millions of patients. This represents a significant shift in how cardiovascular disease detection might work in the future, moving from reactive diagnosis after symptoms appear to proactive identification of disease patterns .

What New Approaches Are Targeting Treatment-Resistant Diseases?

Beyond diagnostic tools, university researchers are developing novel therapeutic approaches for diseases that have historically resisted conventional treatments. For patients with systemic amyloidosis, a rare and deadly condition characterized by the buildup of misfolded proteins in vital organs, current treatments can only slow disease progression. Around 80% of amyloidosis patients remain undiagnosed, and those diagnosed face a short survival window that demands earlier intervention .

Attralus, a biopharmaceutical company launched with technology licensed from the University of Tennessee Research Foundation, is developing a new class of drugs designed to bind directly to amyloid deposits and eliminate them from tissues, rather than simply slowing their formation. The company's technology originated from decades of research led by Jonathan Wall and colleagues in the Amyloidosis and Cancer Theranostics Program at the University of Tennessee Health Science Center College of Medicine in Knoxville. In 2026, pharmaceutical company Bayer acquired two investigational imaging agents developed by this program, tools designed to improve early diagnosis and monitoring of cardiac amyloidosis .

Another challenge in modern medicine involves delivering RNA-based medicines safely to the right cells in the body. Orion Therapeutics, a Knoxville-based biotechnology company, is developing a proprietary non-viral delivery platform for RNA medicines. The company was co-founded by Trey Fisher and Deidra Mountain, a professor at the University of Tennessee Health Science Center College of Medicine in Knoxville and director of Orion's Vascular Therapeutic Pipeline. Supported by the University of Tennessee Research Foundation's Accelerate Fund, which invests in startup companies at early development stages, Orion is developing its GENESYS lipid nanoparticle delivery platform to enable safer, more effective delivery of RNA-based therapeutics .

Researchers are also advancing experimental drugs to treat advanced prostate cancer and brain tumors, diseases that often develop resistance to existing treatments. Innovators Duane Miller, Ramesh Narayanan, and Lawrence Pfeffer co-founded RAMiller LLC to develop drugs discovered in their laboratories, recognizing that drug discovery can impact thousands or hundreds of thousands of patients simultaneously .

How Are Surgical Innovations Improving Patient Outcomes?

Beyond pharmaceuticals and diagnostics, researchers are developing precision surgical instruments that improve consistency and reduce complications. Edward Chaum, former Plough Foundation Professor at the University of Tennessee Health Science Center Hamilton Eye Institute, and engineers at Oak Ridge National Laboratory developed Plexitome, a surgical instrument designed to treat corneal abrasions and recurrent corneal erosion, conditions that affect more than one million patients each year .

The device contains hundreds of microscopic spikes engineered to create controlled punctures in the cornea, helping strengthen epithelial attachment and promote healing while minimizing scarring. Traditional surgical techniques can be inconsistent, but this device allows surgeons to create uniform patterns that may reduce recurrence and improve recovery .

"We designed the device to deliver precision and consistency. Ultimately, that means better outcomes for patients," explained Edward Chaum.

Edward Chaum, Former Plough Foundation Professor, University of Tennessee Health Science Center Hamilton Eye Institute

Licensed through the University of Tennessee Research Foundation, the technology is now being distributed for clinical use through VEO Ophthalmics, bringing this precision instrument to eye care clinics across the country .

What Role Does Personalized Medicine Play in Mental Health Monitoring?

Beyond physical diseases, researchers are exploring how mobile and wearable technologies can support mental health care. A comprehensive review of 52 studies published in Nature examined how smartphones and wearable devices can continuously monitor behavioral, psychological, and physiological data to predict changes in depression symptoms before they become severe .

The research identified several key data points that show strong associations with depressive symptoms, including time spent at home, sleep variability, reduced mobility, physical activity patterns, heart rate variability, and mood self-reports. Features such as time spent at home, sleep variability, and reduced mobility were strongly associated with depressive symptoms. Combining physiological, behavioral, and self-report data enhanced predictive performance compared to using any single type of data alone .

Importantly, personalized models that account for individual differences outperformed generalized models in predicting symptom changes. This suggests that the most effective digital mental health tools will be tailored to each person's unique patterns rather than applying one-size-fits-all algorithms. Mobile and wearable data show strong potential for just-in-time depression prediction, enabling interventions at the moment when someone needs support most .

The convergence of these innovations, from AI-powered diagnostics to precision surgical tools to personalized mental health monitoring, reflects a broader shift in medicine toward earlier detection, more targeted treatment, and continuous patient monitoring. As university researchers continue advancing these discoveries with support from research foundations and partnerships with industry, the gap between laboratory breakthrough and patient benefit continues to narrow, bringing hope to millions of people living with serious health conditions.